IGFBPL1 and Bjornstad syndrome: The most commonly employed clinical test for predicting imminent PTD are quantitative fetal fibronectin (qfFN) and insulin-like growth factor binding protein-1 (Actim Partus) [4–7], however, due to the heterogeneity of the pathophysiology of PTD, several studies have explored other maternal clinical, inflammation and biochemical markers to predict PTD within 7–14 days in women presenting with symptoms of PTL [3, 8].